Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis

Eljaaly, Khalid; Wali, Haytham; Basilim, Ahmed; Alharbi, Aisha; Asfour, Hani Z.

doi:10.1016/j.ijantimicag.2019.05.023

Cited by 21 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…21 However, 2 recent meta-analyses highlighted the superior role of ceftaroline to ceftriaxone for the treatment of MRSA. 22,23 In the CAPTURE study, real-world observational data supported the use of ceftaroline as an alternative to ceftriaxone for the empirical treatment of adult patients hospitalized with CAP, considering also its safety profile. 24,25 In the CAPTURE study was evaluated the outcome of patients who were excluded in the original Phase 3 trials in a noncomparative fashion, providing valuable informations about ceftaroline use in special populations such as MRSA CAP, elderly, critically ill patients, and those with renal failure.…”

Section: Ceftarolinementioning

confidence: 98%

Spotlight on New Antibiotics for the Treatment of Pneumonia

Russo

2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

In the last years, the presence of multidrug-resistant (MDR) Gram-negative (like Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii) and Gram-positive bacteria (mostly methicillin-resistant Staphylococcus aureus) was worldwide reported, limiting the options for an effective antibiotic therapy. For these reasons, inappropriate antimicrobial therapy and delayed prescription can lead to an unfavorable outcome, especially in patients with pneumonia. New antibiotics approved belong to classes of antimicrobials, like beta-lactams with or without beta-lactamase inhibitors, aminoglycosides, oxazolidinones, quinolones, and tetracyclines, or based on new mechanisms of action. These new compounds show many advantages, including a broad spectrum of activity against MDR pathogens, good lung penetration, safety and tolerability, and finally the possibility of intravenous and/or oral formulations. However, the new antibiotics under development represent an important possible armamentarium against difficult-to-treat strains. The safety and clinical efficacy of these future drugs should be tested in clinical practice. In this review, there are reported characteristics of newly approved antibiotics that represent potential future options for the treatment of respiratory tract infections, including those caused by multidrug-resistant bacteria. Finally, the characteristics of the drugs under development are briefly reported.

show abstract

Section: Ceftarolinementioning

confidence: 98%

Spotlight on New Antibiotics for the Treatment of Pneumonia

Russo

2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

show abstract

“…Furthermore, ceftaroline is a favourable option in Staphylococcalpneumonia, according to its higher ELF penetration than glycopeptides and low risk of nephrotoxicity. Staphylococcus-related pneumonia might be secondary to a previous or current bacteremia, as reported for central venous catheter (CVC) related bloodstream infections or infectious endocarditis: involvement of the lungs, as multifocal pneumonia spreading from septic embolism, could be in the presence of specific interest of this extendedspectrum cephalosporin (15,28,159,160).…”

Section: Place In Therapy Of Ceftaroline Within Imwsmentioning

confidence: 99%

“…Ceftaroline as for ceftobiprole may be first-line agents, flanked by neuraminidase inhibitors, in severe CAP complicating influenza for their known anti-MRSA activity (Figure 1) (15,28,(159)(160)(161)(162).…”

Section: Place In Therapy Of Ceftaroline Within Imwsmentioning

confidence: 99%

New cephalosporins for the treatment of pneumonia in internal medicine wards

et al. 2020

View full text Add to dashboard Cite

The burden of hospital admission for pneumonia in internal medicine wards may not be underestimated; otherwise, cases of pneumonia are a frequent indication for antimicrobial prescriptions. Community-and hospital-acquired pneumonia are characterized by high healthcare costs, morbidity and non-negligible rates of fatality. The overcoming prevalence of resistant gram-negative and positive bacteria (e.g., methicillin-resistant Staphylococcus aureus, penicillin and ceftriaxone-resistant Streptococcus pneumoniae, extended-spectrum β-lactamases and carbapenemases producing Enterobacteriaceae) has made the most of the first-line agents ineffective for treating lower respiratory tract infections. A broad-spectrum of activity, favourable pulmonary penetration, harmlessness and avoiding in some cases a combination therapy, characterise new cephalosporins such as ceftolozane/tazobactam, ceftobiprole, ceftazidime/avibactam and ceftaroline. We aimed to summarise the role and place in therapy of new cephalosporins in communityand hospital-acquired pneumonia within the setting of internal medicine wards. The "universal pneumonia antibiotic strategy" is no longer acceptable for treating lung infections. Antimicrobial therapy should be individualized considering local antimicrobial resistance and epidemiology, the stage of the illness and potential host factors predisposing to a high risk for specific pathogens.

show abstract

“…A recent meta-analysis comparing ceftriaxone with ceftaroline or ceftobiprole identified five RCTs and a total of 77 patients with community-acquired pneumonia secondary to MSSA. Patients treated with ceftriaxone demonstrated higher rates of treatment failure [28]. None of our included studies contained patients with MSSA pneumonia or comparator groups treated with 5th generation cephalosporins.…”

Section: Comparison With Other Literaturementioning

confidence: 99%

Intravenous Ceftriaxone Versus Multiple Dosing Regimes of Intravenous Anti-Staphylococcal Antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA): A Systematic Review

et al. 2020

View full text Add to dashboard Cite

Background: Methicillin-susceptible Staphylococcus aureus (MSSA) is a common pathogen associated with a range of clinically important infections. MSSA can cause deep-seated infections requiring prolonged courses of intravenous antibiotic therapy to achieve effective resolution. The move toward ambulatory or outpatient delivery of parenteral antibiotics has led to an increase in the use of ceftriaxone as a pragmatic first choice given its advantageous single daily dosing schedule. Objective: To compare the efficacy of once daily ceftriaxone in the treatment of infections due to confirmed or suspected MSSA to multiple dosing regimes of anti-staphylococcal antibiotics. Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE), Global Health, PubMed, EMBASE and CINAHL for randomised controlled trials as well as prospective and retrospective cohort studies that compared ceftriaxone to any multiple dosing regime of anti-staphylococcal antibiotics. Outcome measures were the proportion of patients with a resolution of infection based on time after initiation of therapy, adverse reactions, recurrence and duration of hospital admission. Results: We included two randomized controlled trials, one prospective observational study and three retrospective cohort studies (643 participants; 246 children, 397 adults). There was no difference in time to resolution of symptoms. The number of adverse reactions, recurrence of bacteraemia and duration of hospital stay were not significantly different between ceftriaxone and other anti-staphylococcal antibiotics. Conclusions: Based on a small number of low-quality studies, ceftriaxone is as effective as multiple dosing regimes for the treatment of infections due MSSA. An appropriately powered randomized trial is required to demonstrate equivalence and cost effectiveness.

show abstract

Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis

Cited by 21 publications

References 28 publications

Spotlight on New Antibiotics for the Treatment of Pneumonia

Spotlight on New Antibiotics for the Treatment of Pneumonia

New cephalosporins for the treatment of pneumonia in internal medicine wards

Intravenous Ceftriaxone Versus Multiple Dosing Regimes of Intravenous Anti-Staphylococcal Antibiotics for Methicillin-Susceptible Staphylococcus aureus (MSSA): A Systematic Review

Contact Info

Product

Resources

About